Company intelligence / Profile preview

QuantuMDx

Newcastle upon Tyne, Tyne and Wear, United Kingdomquantumdx.com ↗

Ownership: Private
Employees: ~121
Development stage: Other

Overview

QuantuMDx has commercialized its Q‑POC™ multiplex PCR point-of-care diagnostic device. The company’s flagship product includes a respiratory panel for rapid detection of SARS-CoV‑2, Flu A/B & RSV with results in approximately 30–35 minutes. The company continues to expand its menu of assays through internal R&D and partnerships[1][2][6].

Therapeutic areas: Infectious Diseases
Modalities: DevicePCR-based diagnostics (Multiplex PCR)Molecular diagnostics platform
Industry: Molecular Diagnostics

Partnerships

Sansure Biotech (global R&D/manufacturing/commercial partnership for China market)

Beyond the preview

Go deeper on QuantuMDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QuantuMDx.

Explore the full profile